Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
November 23, 2021 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements...
Supernus to Participate in Annual Piper Sandler Healthcare Conference
November 18, 2021 08:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Upcoming November Investor Conferences
November 10, 2021 16:05 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Third Quarter 2021 Financial Results
November 03, 2021 16:01 ET
|
Supernus Pharmaceuticals, Inc.
Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020Third quarter 2021 total revenues were $148.5 million, a...
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
October 27, 2021 17:42 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month
October 20, 2021 08:00 ET
|
Supernus Pharmaceuticals, Inc.
Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversityNearly one-in-ten – or 6.1 million children and adolescents...
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
October 11, 2021 06:30 ET
|
Supernus Pharmaceuticals, Inc.
Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to...
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
September 02, 2021 18:45 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Upcoming September Investor Conferences
September 02, 2021 09:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2021 Financial Results
August 04, 2021 16:09 ET
|
Supernus Pharmaceuticals, Inc.
Second quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020Qelbree™ launched in the U.S. for pediatric ADHD at the end of May 2021Qelbree sNDA for adult ADHD submitted to the...